Confidence through Global Experience over 2 decades

Octaplasma® is the most extensively used pathogen-inactivated plasma worldwide.1

Octaplasma®

Global experience

The introduction of Octaplasma® as the exclusive plasma for transfusion in several European countries has resulted in better outcomes for patients and health systems.​


>11.86

Million bags infused†

globally

>3.95

Million patients treated†

globally

>91,000

Bags infused and >1000 patients treated††

in Canada

Finland

Reduction in Severe Adverse Events (SAE)

In Finland, 84% drop in Serious Adverse Events (SAE) was reported in the first year of nationwide usage of Octaplasma®*2

Europe

Significant reduction in Adverse Drug Reactions

Recent Hemovigilance data from 8 European countries show a significant reduction in Adverse Drug Reactions with Octaplasma® 3

Norway

No incidence of TRALI based on haemovigilance data7

In Norway, where Octaplasma® has replaced other fluids since 1993, TRALI has not been reported. This is in contrast to other Nordic countries like Sweden and Finland where FFP was used in the observed period7

Octaplasma® conforms with AABB TRALI risk mitigation standards6

The Netherlands

National Switch from FFP to Octaplasma reduced plasma usage and anaphylactic reactions8

In the Netherlands, there was a switch from using ~300ml FFP to 200 ml S/D plasma. It was reported that the switch to S/D plasma units, despite being 1/3 smaller in volume than FFP units, was not associated with a higher plasma/RBC ratio.

A potential saving in the volume of plasma used would have benefits to the overall system, donor population and healthcare costs.

Octaplasma® first global registration: 1993

† Worldwide sales data (1989-2022)

†† Canadian sales data (2017-2022)

  1. Data on file, Octapharma Canada Inc. and Octapharma Global (Octapharma MIS Citrix)
  2. Krusius T, Auvinen M-K, Tuimala (2010) Introduction of octaplas in clinical use decreased the rate of serious adverse reactions. Vox Sang 99(Suppl 1):P-1018 (Finnish Red Cross Blood Service, Helsinki, Finland. (Poster: 2010; Octapharma data on file)
  3. Gareis, Michelle, S. Wietek, and B. Rohrbacher. “Haemovigilance experience with S/D treated plasma (octaplas®) and fresh frozen plasma.” Journal of Cardiothoracic and Vascular Anesthesia 32 (2018): S33-S34.
  4. OctaplasmaTM Product Monograph, October 31 2022.
  5. Public Health Agency of Canada. Transfusion Transmitted Injuries Surveillance System (TTISS) 2006-2012 Summary Results. Government of Canada. https://www.canada.ca/en/public-health/services/surveillance/blood-safety-contribution-program/transfusion-transmitted-injuries-surveillance-system/2006-2012-summary-results.html. Published July 24, 2014. Accessed September 13, 2022.
  6. American Association of Blood Banks, Bulletin #14-02. Jan. 2014
  7. Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med. 2007;33 Suppl 1:S17-S21.
  8. Saadah et al. Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks Haematologica 2020